$WOCKPHARMA

Pharmaceutical major Wockhardt jumped more than 10% on Monday after the company received approval from the US Food and Drug Administration (FDA) for its novel antibiotic, Zaynich, marking a significant achievement in its long-standing research and development efforts. The stock surged as much as 16.2% in early trade following the announcement before trimming some gains. At 9:42 am, Wockhardt shares were trading 12.2% higher at Rs 2,279 on the NSE. Zaynich has been approved for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and is specifically designed to combat infections caused by drug-resistant Gram-negative bacteria. The approval comes at a time when antimicrobial resistance is becoming an increasingly serious global health concern, reducing available treatment options for healthcare providers. Wockhardt's antibiotic development programme addresses a critical unmet need in the healthcare industry, particularly as several large multinational pharmaceutical companies have scaled back investments in antibiotic research. The company has focused its efforts on tackling Gram-negative resistant infections, which are among the most challenging and rapidly evolving threats in infectious disease treatment. According to company estimates, nearly two million patients worldwide are affected by Gram-negative resistant infections. Wockhardt believes Zaynich has a total addressable market of approximately $9 billion across the United States, Europe, and India. In India, the company estimates that around 1.1 million resistant infection cases could potentially benefit from the drug, representing a market opportunity of nearly Rs 17,000 crore. In the US and European markets combined, Wockhardt estimates the addressable opportunity at roughly $7 billion.